Press releases

GSK exercises option on phase I/II NY-ESO T-cell therapy (GSK3377794)

Today GSK announced that it has exercised the option to obtain an exclusive global license from Adaptimmune for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1 (GSK3377794). Upon exercise of this option and transition of the programme, GSK will assume responsibility for all development, manufacturing and commercialisation activities for the asset.

Read more - GSK exercises option on phase I/II NY-ESO T-cell therapy (GSK3377794) Read more